Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492

1.

Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Sep 13. doi: 10.1038/s41391-018-0090-5. [Epub ahead of print]

PMID:
30214036
2.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary.

Bekelman JE, Rumble RB, Freedland SJ.

J Oncol Pract. 2018 Sep 10:JOP1800434. doi: 10.1200/JOP.18.00434. [Epub ahead of print] No abstract available.

PMID:
30199312
3.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ.

J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606. [Epub ahead of print]

PMID:
30183466
4.

Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?

Allott EH, Freeman MR, Freedland SJ.

Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30597-9. doi: 10.1016/j.eururo.2018.08.012. [Epub ahead of print] No abstract available.

PMID:
30177293
5.

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH.

Cancer Prev Res (Phila). 2018 Aug 23. doi: 10.1158/1940-6207.CAPR-18-0057. [Epub ahead of print]

PMID:
30139875
6.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) Group.

J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.05.164. [Epub ahead of print] Review.

PMID:
30077557
7.

The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme.

Schwarzman LS, Abern MR, Garvey DF, Andriole GL, Freedland SJ, Moreira DM.

J Urol. 2018 Jun 12. pii: S0022-5347(18)43356-3. doi: 10.1016/j.juro.2018.06.018. [Epub ahead of print]

PMID:
29906435
8.

Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.

Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.

PMID:
29902938
9.

Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.

Kuang AG, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

BJU Int. 2018 Jun 6. doi: 10.1111/bju.14428. [Epub ahead of print]

PMID:
29873889
10.

Smoking and Death From Prostate Cancer.

Freedland SJ.

JAMA Oncol. 2018 Jul 1;4(7):961-962. doi: 10.1001/jamaoncol.2018.1070. No abstract available.

PMID:
29800137
11.

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.

Allott EH, Masko EM, Freedland AR, Macias E, Pelton K, Solomon KR, Mostaghel EA, Thomas GV, Pizzo SV, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):196-203. doi: 10.1038/s41391-018-0045-x. Epub 2018 May 23.

PMID:
29795142
12.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.

Patel DN, Feng T, Simon RM, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Roehrborn C, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):238-244. doi: 10.1038/s41391-018-0044-y. Epub 2018 May 23.

PMID:
29795141
13.

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.

Eur Urol. 2018 Aug;74(2):197-203. doi: 10.1016/j.eururo.2018.05.003. Epub 2018 May 16.

PMID:
29778349
14.

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.

PMID:
29758219
15.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

16.

Robust genomic copy number predictor of pan cancer metastasis.

Pearlman A, Upadhyay K, Cole K, Loke J, Sun K, Fineberg S, Freedland SJ, Shao Y, Ostrer H.

Genes Cancer. 2018 Jan;9(1-2):66-77. doi: 10.18632/genesandcancer.165.

17.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246-X. doi: 10.1016/j.eururo.2018.03.028. [Epub ahead of print] Review.

PMID:
29673712
18.

Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial.

Allott EH, Markt SC, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Mucci LA, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):783-789. doi: 10.1158/1055-9965.EPI-18-0076. Epub 2018 Apr 18.

PMID:
29669727
19.

Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ.

Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.

PMID:
29663110
20.

Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.

Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB.

Cancer. 2018 Aug 1;124(15):3127-3135. doi: 10.1002/cncr.31404. Epub 2018 Apr 16.

PMID:
29660813
21.

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ.

BJU Int. 2018 Jul;122(1):76-82. doi: 10.1111/bju.14193. Epub 2018 Apr 10.

PMID:
29521009
22.

Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ.

BJU Int. 2018 Feb 23. doi: 10.1111/bju.14178. [Epub ahead of print]

PMID:
29473992
23.

First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.

McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ.

Urol Oncol. 2018 May;36(5):239.e17-239.e25. doi: 10.1016/j.urolonc.2018.01.005. Epub 2018 Feb 9.

PMID:
29429895
24.

Individualizing PSA Monitoring Among Older Prostate Cancer Survivors.

Shi Y, Fung KZ, John Boscardin W, Ngo S, Freedland SJ, Wong ML, Walter LC.

J Gen Intern Med. 2018 May;33(5):602-604. doi: 10.1007/s11606-018-4334-9. No abstract available.

PMID:
29417461
25.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.

PMID:
29331546
26.

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):252-259. doi: 10.1038/s41391-017-0030-9. Epub 2017 Dec 27.

27.

20 years-A retrospective of prostate cancer and prostatic diseases.

Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):1-3. doi: 10.1038/s41391-017-0025-6. Epub 2017 Dec 19. No abstract available.

PMID:
29259294
28.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
29.

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

J Urol. 2018 Jun;199(6):1459-1463. doi: 10.1016/j.juro.2017.11.113. Epub 2017 Dec 6.

PMID:
29223389
30.

Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.

Xiao J, Howard L, Wan J, Wiggins E, Vidal A, Cohen P, Freedland SJ.

Oncotarget. 2017 Aug 10;8(55):94900-94909. doi: 10.18632/oncotarget.20134. eCollection 2017 Nov 7.

31.

Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.

Moreira DM, Andriole GL, Castro-Santamaria R, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):106-112. doi: 10.1038/s41391-017-0012-y. Epub 2017 Dec 4.

PMID:
29203895
32.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15.

PMID:
29203269
33.

An update of research evidence on nutrition and prostate cancer.

Lin PH, Aronson W, Freedland SJ.

Urol Oncol. 2017 Nov 2. pii: S1078-1439(17)30536-7. doi: 10.1016/j.urolonc.2017.10.006. [Epub ahead of print] Review.

PMID:
29103966
34.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Dec;77(16):1592-1600. doi: 10.1002/pros.23436. Epub 2017 Oct 10.

PMID:
28994485
35.

Angiotensin receptor signaling and prostate tumor growth in mice.

Scott-Emuakpor J, Allot E, Johnson SA, Howard LE, Macias E, Freedland SJ, Gurley SB.

J Exp Ther Oncol. 2017 Sep;11(2):107-115.

PMID:
28976133
36.

Are You What You Eat or What Your Mother Ate or Both?

Freedland SJ.

Cancer Prev Res (Phila). 2017 Oct;10(10):551-552. doi: 10.1158/1940-6207.CAPR-17-0224. Epub 2017 Sep 20.

PMID:
28931505
37.

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.

Oncotarget. 2017 Feb 7;8(31):50804-50813. doi: 10.18632/oncotarget.15133. eCollection 2017 Aug 1.

38.

Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.

Branche BL, Howard LE, Moreira DM, Roehrborn C, Castro-Santamaria R, Andriole GL, Hopp ML, Freedland SJ.

J Urol. 2018 Feb;199(2):536-542. doi: 10.1016/j.juro.2017.08.108. Epub 2017 Sep 1.

PMID:
28870861
39.

Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.

Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

J Urol. 2018 Mar;199(3):713-718. doi: 10.1016/j.juro.2017.08.107. Epub 2017 Sep 1.

PMID:
28870860
40.

Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urology. 2017 Dec;110:76-83. doi: 10.1016/j.urology.2017.08.024. Epub 2017 Aug 25.

PMID:
28847688
41.

Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.

Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB.

Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30215-X. doi: 10.1016/j.clgc.2017.07.018. [Epub ahead of print]

PMID:
28826932
42.

Response to Editorial Comment to Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Freedland SJ, Howard LE.

Int J Urol. 2017 Aug;24(8):624-625. doi: 10.1111/iju.13426. No abstract available.

43.

In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.

Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Eur Urol Focus. 2017 Oct;3(4-5):480-486. doi: 10.1016/j.euf.2016.08.007. Epub 2016 Aug 29.

PMID:
28753787
44.

Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.

Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ.

Urology. 2017 Oct;108:129-134. doi: 10.1016/j.urology.2017.07.009. Epub 2017 Jul 19.

PMID:
28735016
45.

Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.

Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

J Urol. 2017 Dec;198(6):1309-1315. doi: 10.1016/j.juro.2017.07.009. Epub 2017 Jul 11.

PMID:
28709888
46.

Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.

47.

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.

Grant DJ, Chen Z, Howard LE, Wiggins E, De Hoedt A, Vidal AC, Carney ST, Squires J, Magyar CE, Huang J, Freedland SJ.

BMC Cancer. 2017 Jul 3;17(1):463. doi: 10.1186/s12885-017-3463-6.

48.

Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.

PMID:
28662291
49.

Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.

Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ; Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group.

Cancer. 2017 Nov 1;123(21):4199-4206. doi: 10.1002/cncr.30834. Epub 2017 Jun 27.

PMID:
28654204
50.

Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.

Williams SB, Huo J, Dafashy TJ, Ghaffary CK, Baillargeon JG, Morales EE, Kim SP, Kuo YF, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urol Oncol. 2017 Oct;35(10):602.e1-602.e9. doi: 10.1016/j.urolonc.2017.05.022. Epub 2017 Jun 21.

PMID:
28647395

Supplemental Content

Loading ...
Support Center